Navigating the complexities of contemporary public health landscapes has never been more challenging for low- and middle-income countries. As health ministries grapple with constrained budgets, shifting epidemiological trends, and an expanding pipeline of innovative pharmaceutical interventions, the strategic selection and sequencing of national immunization portfolios have become high-stakes endeavors. Determining which vaccines to introduce, the precise order of integration, and how to maximize health outcomes within strict fiscal envelopes requires sophisticated decision-making tools and rigorous evidentiary frameworks. For more than three decades, JSI has stood at the forefront of this global health challenge, providing technical assistance and strategic guidance to support over 20 countries in fortifying their national immunization programs. Building upon this long-standing commitment, JSI recently spearheaded the CHOICES 2.0 initiative, a landmark project designed to revolutionize how National Immunization Technical Advisory Groups (NITAGs) and Expanded Programs on Immunization (EPI) approach new vaccine introduction prioritization and portfolio optimization.
The Genesis of CHOICES 2.0 and the Evolution of Vaccine Prioritization
The CHOICES 2.0 project emerged as a direct response to the mounting pressures faced by national health authorities. In an era defined by overlapping economic crises, post-pandemic resource contractions, and the persistent threat of emerging infectious diseases, the margin for error in public health investments is razor-thin. To address these vulnerabilities, JSI channeled its extensive field experience alongside deep partnerships with premier global immunization experts and technical working groups. Through CHOICES 2.0, the organization provided targeted, hands-on support to NITAGs and national immunization secretariats, enabling them to conduct systematic evaluations of potential new vaccine introductions.
At the heart of this operational framework lies the New Vaccine Introduction Prioritization and Sequencing Toolkit (NVI-PST). The NVI-PST was originally conceptualized and developed by Development Catalysts in close collaboration with the inaugural CHOICES project—an initiative led by the International Vaccine Access Center (IVAC) and supported by JSI, the United States Centers for Disease Control and Prevention (US CDC), and Development Catalysts, in partnership with the World Health Organization (WHO) and the Global NITAG Network. Built upon a robust Multi-Criteria Decision Analysis (MCDA) approach, the toolkit integrates empirical country-level learning to help decision-makers evaluate a multifaceted array of criteria, including disease burden, vaccine efficacy, cost-effectiveness, programmatic feasibility, and equity considerations.
Throughout the lifecycle of the CHOICES 2.0 project, leadership engaged proactively with stakeholders at both global and regional levels, particularly across the African continent. This continuous dialogue ensured that project methodologies remained closely aligned with evolving Vaccine Prioritization and Optimization (VPOP) processes and the strategic objectives of the Global NITAG Network. By bridging the gap between high-level global policy and localized implementation, CHOICES 2.0 established a scalable model for evidence-based public health planning.
A Chronological Overview of Implementation and Outreach
The operational timeline of the CHOICES 2.0 initiative reflects a deliberate, phased strategy designed to maximize reach and institutional capacity-building among Gavi-eligible nations. The foundational phases of the project involved refining the MCDA methodologies and updating the NVI-PST to incorporate newly developed optimization modules, ensuring that the toolkit could address not only single-vaccine introductions but also complex portfolio sequencing decisions.
Between 2025 and 2026, the project entered its intensive country engagement phase. JSI and its consortium partners convened a series of targeted in-person and virtual workshops. These sessions were specifically curated for Gavi-eligible countries that had formally requested engagement or accepted invitations extended by CHOICES 2.0 leadership. Convened directly by national NITAGs, these workshops served as collaborative forums where multidisciplinary teams could systematically analyze their national immunization programs, weigh competing vaccine priorities, and draft optimized introduction roadmaps. Across the combined trajectories of the original CHOICES and CHOICES 2.0 projects, JSI and its partners provided direct, intensive workshop support to seven countries, facilitating deep dives into epidemiological data and financial forecasting.
Recognizing that in-person workshops, while highly effective, could only reach a finite number of national experts, the project expanded its pedagogical footprint through a strategic partnership with the National Immunization Technical Advisory Group Support Hub (NISH) at the University of Cape Town and the World Health Organization (WHO). Together, these entities designed and hosted a comprehensive five-part webinar series entitled Applying Vaccine Prioritization Strategies for Optimized Public Health Outcomes.
This virtual capacity-building campaign featured presentations and panel discussions led by subject-matter experts from NISH, JSI, WHO, UNICEF, and active NITAG representatives. The curriculum was meticulously structured to guide participants through the foundational principles of the new vaccine prioritization process, provide hands-on demonstrations of the NVI-PST and its newly released Optimization Module, examine real-world case studies of successful tool implementation, and explore how these quantitative instruments complement existing international decision-support frameworks.
The virtual format proved to be a resounding success, attracting active NITAG members and EPI representatives from 19 countries. Beyond delivering critical technical instruction, the webinar series democratized access to cutting-edge prioritization methodologies, catalyzed vibrant cross-country learning, and facilitated peer-to-peer exchange of best practices among immunization professionals operating in diverse geopolitical and economic settings.
Demographic and Institutional Insights from Supporting Data
An examination of the quantitative footprint left by the CHOICES and CHOICES 2.0 projects underscores the vast scale of technical assistance delivered over the past decade. By operating at the intersection of rigorous data analysis and institutional capacity-building, JSI and its collaborators successfully supported more than 20 countries in refining their national vaccine prioritization and optimization strategies.
Despite these remarkable achievements, the supporting data and post-workshop evaluations reveal persistent systemic hurdles that threaten the long-term sustainability of independent decision-making. While a select group of participating nations possessed the domestic financial resources and institutional autonomy to sustain the prioritization process independently, the vast majority of countries articulated an acute need for ongoing external support. Specifically, national stakeholders highlighted critical data gaps, noting that timely access to granular epidemiological data, accurate local disease burden metrics, transparent vaccine market intelligence, and comprehensive performance data from comparable peer settings remain indispensable prerequisites for defensible policymaking.
Furthermore, an institutional analysis of NITAG structures across the global south highlights a pervasive human resource constraint. The overwhelming majority of NITAG members serve on a strictly voluntary basis, balancing their advisory duties with demanding full-time clinical, academic, or administrative positions within their home health systems. Consequently, the meticulous tasks of gathering disparate datasets, conducting advanced MCDA modeling, synthesizing complex evidence briefs, and formulating actionable policy recommendations place an extraordinary burden on already overextended public health professionals.
Official Responses and Perspectives from the Global Health Community
Leaders within the international public health community have been vocal about the indispensable role that structured prioritization frameworks play in safeguarding immunization gains amidst tightening global fiscal constraints. Representatives from the WHO and UNICEF have frequently emphasized that as external donor funding plateaus and domestic health budgets face competing pressures, countries can no longer afford to adopt new vaccines in an ad hoc, reactive manner.
Global health economists and NITAG secretariat coordinators have commended initiatives like CHOICES 2.0 for addressing not only the technical dimensions of decision-making but also the human and political prerequisites for sustainable policy execution. In official feedback compiled during project evaluations, NITAG members repeatedly noted that the administrative and technical facilitation provided by JSI was instrumental in breaking through bureaucratic inertia. By supplying dedicated administrative bandwidth, neutral facilitation, and complementary financial support for meetings and workshops, the project helped cultivate high-level political buy-in from Ministries of Health. This institutional backing ensured that national experts were granted the protected time and organizational space necessary to engage deeply with the prioritization process.
Experts from the Global NITAG Network have likewise stressed that institutionalizing these prioritization practices requires a permanent, enabling environment. No single workshop or webinar series can substitute for a resilient national ecosystem wherein Ministries of Health, EPI managers, academic researchers, and international technical partners work in seamless synchronization.
Broader Implications and the Future Path of Vaccine Optimization
The implications of the CHOICES 2.0 initiative extend far beyond the immediate technical outputs of workshops and webinars; they represent a fundamental paradigm shift in how developing nations approach health security and universal health coverage. As the global community confronts an increasingly volatile epidemiological landscape characterized by recurring disease outbreaks, antimicrobial resistance, and the rapid commercialization of novel vaccine technologies—such as malaria vaccines, respiratory syncytial virus (RSV) monoclonal antibodies, and next-generation pneumococcal formulations—the complexity of portfolio management will only intensify.
In this context, the institutionalization of tools like the NVI-PST is no longer a luxury, but a core competency of modern health governance. Countries that successfully integrate Multi-Criteria Decision Analysis into their routine planning cycles are better positioned to negotiate favorable vaccine pricing, optimize cold-chain logistics, maximize equitable coverage, and demonstrate verifiable return on investment to domestic legislatures and international donors alike.
However, realizing this vision of self-sustaining, evidence-based prioritization requires a deliberate, long-term commitment from the global health architecture. As the CHOICES 2.0 project concludes its active implementation phase, the onus falls upon national governments and international resource partners to preserve and expand the institutional gains achieved thus far. Ministries of Health must formalize the integration of the NVI-PST into national health sector strategic plans, allocate dedicated domestic budget lines to support NITAG operations, and institutionalize continuous professional development for advisory board members.
Concurrently, global technical working groups, the Global NITAG Network, and multilateral agencies must maintain robust support mechanisms, ensuring that countries retain access to updated market intelligence, methodological training, and collaborative peer networks. By addressing the fundamental human resource and data constraints that have historically hampered local decision-making, the global health community can ensure that every vaccine dollar is deployed with maximum precision—ultimately protecting vulnerable populations, strengthening health system resilience, and advancing the frontiers of global health equity for generations to come.
